Elsevier

Journal of Psychiatric Research

Volume 82, November 2016, Pages 8-15
Journal of Psychiatric Research

Prefrontal changes in the glutamate-glutamine cycle and neuronal/glial glutamate transporters in depression with and without suicide

https://doi.org/10.1016/j.jpsychires.2016.06.017Get rights and content

Abstract

There are indications for changes in glutamate metabolism in relation to depression or suicide. The glutamate-glutamine cycle and neuronal/glial glutamate transporters mediate the uptake of the glutamate and glutamine. The expression of various components of the glutamate-glutamine cycle and the neuronal/glial glutamate transporters was determined by qPCR in postmortem prefrontal cortex. The anterior cingulate cortex (ACC) and the dorsolateral prefrontal cortex (DLPFC) were selected from young MDD patients who had committed suicide (MDD-S; n = 17), from MDD patients who died of non-suicide related causes (MDD-NS; n = 7) and from matched control subjects (n = 12). We also compared elderly depressed patients who had not committed suicide (n = 14) with matched control subjects (n = 22). We found that neuronal located components (EAAT3, EAAT4, ASCT1, SNAT1, SNAT2) of the glutamate-glutamine cycle were increased in the ACC while the astroglia located components (EAAT1, EAAT2, GLUL) were decreased in the DLPFC of MDD-S patients. In contrast, most of the components in the cycle were increased in the DLPFC of MDD-NS patients. In conclusion, the glutamate-glutamine cycle - and thus glutamine transmission - is differentially affected in depressed suicide patients and depressed non-suicide patients in an area specific way.

Introduction

Suicide is an important public health problem that has a strong association with psychopathology, in particular with mood disorders (Hawton and van Heeringen, 2009). A large body of evidence suggests that neurobiological factors play an important role in the predisposition to suicide (Ernst et al., 2009b, Mann and Currier, 2012). Although there is some overlap, this neurobiological predisposition appears to differ considerably from the predisposition to mood disorders per se, especially in the case of major depressive disorder (MDD) (Egeland and Sussex, 1985, Mann and Currier, 2010, Turecki, 2014).

The prefrontal cortex (PFC) is one of the major brain structures to modulate the stress response. It can be stimulatory or inhibitory, depending on specific sub-regions or stressor types. The PFC has also been implicated in mood disorders and there is a negative correlation between the severity of post-stroke depression and the distance between the brain injury site and the frontal pole (Narushima et al., 2003). Furthermore, dysfunctioning anterior cingulate cortex (ACC) and dorsolateral prefrontal cortex (DLPFC) were shown by functional and structural imaging in MDD (Drevets, 2000, Drevets et al., 2008) as well as altered glucose metabolism and blood flow (Drevets, 1999, Mayberg, 2003, Seminowicz et al., 2004). Also postmortem data support PFC involvement in MDD: e.g. reduced glial cell density and neuronal size were observed in the ACC and DLPFC (Cotter et al., 2001, Cotter et al., 2002, Rajkowska and Miguel-Hidalgo, 2007, Rajkowska et al., 1999).

Recent large-scale gene array studies in post-mortem subjects have provided strong support for alterations in GABAergic and glutamatergic neurotransmission in the PFC of depression (Bernard et al., 2011, Choudary et al., 2005, Duric et al., 2013). However, these postmortem studies consisted largely of psychiatric patients who had committed suicide, whereas none of the subjects in the control group had a psychiatric disease during their lifetime or committed suicide. Therefore it remains unclear whether these changes in the PFC were related to depression or to suicide per se.

In a recent study we found that only few GABA and glutamate-related genes were different in the ACC of elderly depressed patients who had not committed suicide (Zhao et al., 2012), while there were obvious changes in depressed patients who had committed suicide (Zhao et al., 2015). The present study therefore studied whether changes in the ACC and DLPFC occur in terms of the glutamate-glutamine cycle and glutamate transporters, in relation to depression with and without suicide.

Glutamate is synthesized from glutamine by glutaminase in neurons. After glutamate is released from the synaptic terminal, it is taken up by astrocytes through high affinity sodium-dependent neuronal glutamate transporters, such as the excitatory amino acid transporter (EAAT) 1 and EAAT2 (Bar-Peled et al., 1997, Chaudhry et al., 1995, Kugler and Schmitt, 2003, Milton et al., 1997), where it is converted back into glutamine by glutamine synthetase (Martinez-Hernandez et al., 1977). Glutamine is then transported back to the neurons by the neutral amino acid transporter (SNAT) 1 and SNAT2, ready for reuse (Melone et al., 2004). Interestingly, brain-derived neurotrophic factor (BDNF)-induced increases in SNAT1 expression are required for the regulation of dendritic length and neuronal complexity during development (Burkhalter et al., 2007), but BDNF is also clearly linked to depression and suicide (Dwivedi et al., 2003, Ernst et al., 2009b, Grah et al., 2014, Qi et al., 2013). This suggests that the glutamate-glutamine cycle is not only an important constituent of the glutamatergic neurotransmission system in physiology, but may also be a vulnerable pathway in psychiatric disorders due to its linkage with both BDNF and glutamate and GABA neurotransmission. Intrasynaptic glutamate can also be taken up by EAAT3 and EAAT4, which are located on neurons (Danbolt, 2001, Rothstein et al., 1994, Yamada et al., 1997). The EAAT family of glutamate transporters shows homology to the neutral amino acid transporters (ASCT) 1 and ASCT2 (Arriza et al., 1993, Utsunomiya-Tate et al., 1996). Studies showed that ASCT1 in glutamate transmission mediates the efflux of glutamate from the neuron into the synaptic junction via calcium-dependent release, and that ASCT2 activity plays an important role in the glutamine-glutamate cycle between neurons and glia by facilitating the efflux of glutamine from glial cells (Broer et al., 1999).

In the present study, we hypothesized that the glutamate-glutamine cycle is impaired in the brains of depressed individuals who committed suicide and that the neuronal and glial glutamate transporters associated with this cycle are dysregulated. Thus, we used real-time quantitative PCR (qPCR) to compare the gene expression patterns in the PFC of the astrocytic glutamate-glutamine cycle and neuronal/glial glutamate transporters in depressed patients in relation to suicide.

Section snippets

Subjects from the Stanley Medical Research Institute (SMRI)

Brain material was obtained from the SMRI, after obtaining permission for a brain autopsy and for the use of the brain material and clinical data for research purposes. Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV diagnoses of MDD were made independently by two senior psychiatrists based on the medical records and, when necessary, telephone interviews with family members. This systematized procedure was carried out as described before (Torrey et al., 2000). The demographic

Changes in glutamate-glutamine cycle gene expression are related to suicide, not to depression

Brain material obtained from the SMRI was analyzed for changes in the genes involved in the glutamate-glutamine cycle and neuronal/glial glutamate transporters. We determined the RNA integrity value (RIN) to assess whether the quality of the human post-mortem tissue RNA isolated from the ACC or DLPFC did not differ between patient groups (Stan et al., 2006). The RIN did not show any significant differences between the diagnostic groups in the SMRI material (RIN value of the ACC from MDD-S

Discussion

In the present study we found in the SMRI cohort that ASCT2 and neuronal located molecule transcript levels were significantly higher in the ACC of MDD-S patients than in the MDD-NS patients or the control subjects. In contrast, decreased ASCT1 and astroglia located molecule transcript level were found in the DLPFC of MDD-S patients compared to MDD-NS patients. Furthermore, most of the target genes were increased when comparing MDD-NS with control subjects in the same brain area. We did not

Funding

This investigation was supported by the Royal Netherlands Academy of Arts and Sciences (10CDP037).

Contributors

J.Zhao, P.J.Lucassen and D.F.Swaab designed the experiments and prepared the manuscript. J.Zhao, D.J. van Wamelena, X-R Qi and S-F Gao performed the experiments. J.Zhao collected data and together with R. W.H.Verwer did Statistical analysis. D.F.Swaab obtained funding.

Acknowledgement

Postmortem brain tissue was donated by The Stanley Medical Research Institute Brain Collection and by the Netherlands Brain Bank. We are indebted to them for providing us with the brain material and patient information. We thank Unga Unmehopa for her technical help, Wilma Verweij and Dr. Helmut Kessels for critical reading of the manuscript.

References (59)

  • I.D. Milton et al.

    Expression of the glial glutamate transporter EAAT2 in the human CNS: an immunohistochemical study

    Brain Res. Mol. Brain Res.

    (1997)
  • G. Rajkowska et al.

    Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression

    Biol. Psychiatr.

    (1999)
  • J.D. Rothstein et al.

    Localization of neuronal and glial glutamate transporters

    Neuron

    (1994)
  • H.B. Schioth et al.

    Evolutionary origin of amino acid transporter families SLC32, SLC36 and SLC38 and physiological, pathological and therapeutic aspects

    Mol. Asp. Med.

    (2013)
  • D.A. Seminowicz et al.

    Limbic-frontal circuitry in major depression: a path modeling metanalysis

    Neuroimage

    (2004)
  • A.D. Stan et al.

    Human postmortem tissue: what quality markers matter?

    Brain Res.

    (2006)
  • H. Tani et al.

    Modulation of epileptiform activity by glutamine and system A transport in a model of post-traumatic epilepsy

    Neurobiol. Dis.

    (2007)
  • E.F. Torrey et al.

    The stanley foundation brain collection and neuropathology consortium

    Schizophr. Res.

    (2000)
  • N. Utsunomiya-Tate et al.

    Cloning and functional characterization of a system ASC-like Na+-dependent neutral amino acid transporter

    J. Biol. Chem.

    (1996)
  • H. Varoqui et al.

    Cloning and functional identification of a neuronal glutamine transporter

    J. Biol. Chem.

    (2000)
  • H. Wang et al.

    Cloning and functional expression of ATA1, a subtype of amino acid transporter A, from human placenta

    Biochem. Biophys. Res. Commun.

    (2000)
  • K. Yamada et al.

    Changes in expression and distribution of the glutamate transporter EAAT4 in developing mouse Purkinje cells

    Neurosci. Res.

    (1997)
  • D. Yao et al.

    A novel system A isoform mediating Na+/neutral amino acid cotransport

    J. Biol. Chem.

    (2000)
  • J. Zhao et al.

    Gene expression of GABA and glutamate pathway markers in the prefrontal cortex of non-suicidal elderly depressed patients

    J. Affect. Disord.

    (2012)
  • J. Zhao et al.

    Different stress-related gene expression in depression and suicide

    J. Psychiatr. Res.

    (2015)
  • O. Bar-Peled et al.

    Distribution of glutamate transporter subtypes during human brain development

    J. Neurochem.

    (1997)
  • Y. Benjamini et al.

    Controlling the false discovery rate: a practical and powerful approach to multiple testing

    J. Roy. Stat. Soc.

    (1995)
  • R. Bernard et al.

    Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression

    Mol. Psychiatr.

    (2011)
  • A. Broer et al.

    The astroglial ASCT2 amino acid transporter as a mediator of glutamine efflux

    J. Neurochem.

    (1999)
  • Cited by (56)

    View all citing articles on Scopus
    View full text